Core Insights - The article highlights the investment strategies and achievements of Paul Franke, a seasoned investor with 39 years of trading experience, emphasizing his contrarian stock selection style and the development of a system called "Victory Formation" for identifying stocks based on supply/demand imbalances [1] Group 1: Investment Strategies - Paul Franke recommends a diversified approach by owning at least 50 well-positioned stocks to achieve regular stock market outperformance [1] - The "Bottom Fishing Club" articles focus on deep value candidates or stocks that are experiencing significant upward momentum reversals [1] - The "Volume Breakout Report" articles discuss positive trend changes supported by strong price and volume trading actions [1] Group 2: Performance and Recognition - Franke was consistently ranked among the top investment advisors nationally during the 1990s and achieved the 1 position in the Motley Fool® CAPS stock picking contest in 2008 and 2009 out of over 60,000 portfolios [1] - As of September 2025, he was ranked in the Top 4% of bloggers by TipRanks® for 12-month stock picking performance based on suggestions made over the last decade [1] Group 3: Risk Management - The article suggests that investors should implement stop-loss levels of 10% or 20% on individual stock choices to manage risk effectively [1]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against RxSight, Inc. due to allegations of violations of federal securities laws, particularly concerning misleading statements and undisclosed challenges affecting the company's performance [4][6]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses exceeding $75,000 in RxSight between May 7, 2024, and July 8, 2025, to discuss their legal options [1]. - There is a deadline of September 22, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against RxSight [4]. - The complaint alleges that RxSight and its executives made false statements regarding the company's sales and utilization, overstated product demand, and failed to meet previously issued financial guidance for fiscal year 2025 [6]. Group 2: Financial Performance and Market Reaction - On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, indicating significant declines in LDD sales, LAL utilization, and overall revenue, leading to a lowered full-year guidance by approximately $42.5 million at the midpoint [7]. - Following the announcement, RxSight's stock price fell by $4.84, or 37.8%, closing at $7.95 per share on July 9, 2025, with unusually heavy trading volume [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2] Group 1: Class Action Details - The class action lawsuit has been filed against RxSight, Inc. for allegedly misleading statements regarding the company's growth and performance during the Class Period [4] - Investors who purchased RxSight securities may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - The lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members in the litigation [2] Group 2: Allegations Against RxSight - The lawsuit claims that RxSight misrepresented the effectiveness of its field organization and the adoption rates of newer customer cohorts, which were actually underperforming [4] - It is alleged that the utilization across the installed base was declining, contradicting the company's claims of rising utilization [4] - As a result of these misleading statements, investors purchased shares at artificially inflated prices, leading to financial damages when the truth was revealed [4] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [3] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [3] - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, further establishing the firm's credibility [3]

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, specifically related to undisclosed challenges in product adoption and subsequent revenue forecast cuts [1][2][4]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. - The case is currently pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596 [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a significant decline in stock price following the announcement of a reduced revenue forecast on April 3, 2025, with shares dropping approximately 38% from $26.12 to $16.21 [5]. - A further revenue forecast cut on July 8, 2025, led to another 38% decline in stock price, from $12.79 to $7.95, attributed to slower LAL utilization and adoption challenges [6].

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. due to alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2] Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2] - It is alleged that the defendants overstated the demand for RxSight's products [2] - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 due to these issues [2] - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the U.S. [4]

Core Viewpoint - The Law Offices of Frank R. Cruz is reminding investors about the September 22, 2025 deadline to participate as a lead plaintiff in a securities fraud class action lawsuit against RxSight, Inc. for investors who acquired its securities during the specified class period [1] Group 1 - The class action lawsuit is on behalf of investors who purchased RxSight, Inc. securities between May 7, 2024, and July 8, 2025 [1] - Investors who lost money on RxSight, Inc. are encouraged to participate in the securities fraud lawsuit [1]

Group 1 - A class action securities lawsuit has been filed against RxSight, Inc. [1]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose critical issues affecting the company's performance [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from November 7, 2024, to July 8, 2025 [3]. - Allegations include: - The company faced "adoption challenges" and structural issues leading to declines in sales and utilization [3]. - Defendants allegedly overstated the demand for RxSight's products [3]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 [3]. - Positive statements made by defendants regarding the company's business and prospects were materially misleading [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by September 22, 2025, to participate in potential recovery [4]. - Registration includes enrollment in a portfolio monitoring software for status updates throughout the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to misleading statements or omissions that inflated the company's stock [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit, titled Makaveev v. RxSight, Inc., is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. Group 3: Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Group 1 - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding potential legal matters [1]